Khorana Risk Score for VTE in Cancer
Predicts risk of venous thromboembolism (VTE) in outpatients with cancer receiving chemotherapy. Guides thromboprophylaxis decisions.
Score interpretation
→ Khorana score ≥3: High VTE risk (~7.1% at 2.5 months). Consider pharmacological thromboprophylaxis with LMWH or DOAC (rivaroxaban/apixaban) if bleeding risk acceptable.
→ Khorana score 1–2: Intermediate VTE risk (~2%). Individualise thromboprophylaxis decision; discuss with patient.
→ Khorana score 0: Low VTE risk (~0.8%). Routine thromboprophylaxis not recommended in ambulatory setting.
Interpretation bands for the Khorana Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Enoxaparin (LMWH) · Anticoagulant
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.